Document 0JEekv1ynYd2dY7rgKV87VbOO

VCi-i AIJD PVC PRODUCERS GZQ'j. STEERING COMMITTEE MEETING \ SPI Conference Room Rev York, Rev York Wednesday, February 2, 1977 9:30 A.M, Please hold February 2nd as a tentative date for a meeting of the VCM/FVC Producers Group Steering Committee. We feel that there vill be sufficient activities to justify a meeting of the Steering Committee at this time. However, v?e vill confirm the meeting and supply a specific agenda as this date approaches. It has been suggested by the Chairman that we attempt to streamline our activities at this meeting. We would, therefore, like to limit attendance to one representative per company unless a second person would be required for proper coverage of your company's interest. Very truly yours, John R. Lawrence Technical Director V^ SPI-10865 minutes SPI Conference Roan New York, New York VCM AND PVC PRODUCERS GROUP STEERING COMMITTEE Wednesday, February 2, 1977 11:00 A.M,_________________ ACTION SUMMARY: 1. New bylaws in preparation for submission to full Producers Group. 2. Health Committee appointed. 3* EPA/EDF Suit Action - SPI will not seek a stay on present Standard. - SPI will file for an expedited review of Suit. - Counsel will attempt to sit in on negotiations. 4. Approved up to $10,000 to counter New Jersey bill that would block vinyl chloride and polyvinyl chloride. 5. Media briefings to be resumed. 6. Nominating Ccaunittee to be appointed. 7. Meeting of full Producers Group to be held in Washington in mid April. THE SOCIETY OF THE PLASTICS INDUSTRY, INC. 355 Lexington Avenue New York, N.Y. 10017 (212)573-9400 SF1-10866 ATTENDEES: Ed Ackerman, Diamond Shamrock, 1100 Superior Avenue, Cleveland, Ohio 44ll4 Gary II. Baice, Beveridge, Fairbanks & Diamond, One Farragut Square South, Washington,D.C. John T. Barr, Air Products 8s Chemicals, Box 538, Allentown, Pa 18105 Dan S. Dixler,'Keller & Heckman, 1150 17th Street, N.W. Washington, D.C. 20036 Robert Ferrante, Hill 8e Knowlton, 633 Third Avenue, New York, N, Y. 10017 Jerome H. Heckman, Keller 8s Heckman, 1150 17th Street, N.W. Washington, D.C. 20036 Harold Himmelroan, Beveridge, Fairbanks & Diamond, One Farragut Square So. Wash. D.C. John R. Lawrence, SPI, 355 Lexington Avenue, New York, N.Y. 10017 D. C. Nuechterlein, Dow Chemical USA, 2020 Dow Center, Midland, Michigan 48640 Frank X. Ritter, Tenneco Inc. Box 365> Piscataway, NJ 08854 Richard D. Savage, B. F. Goodrich Chemical Corp. 6100 Oak Tree Blvd. Cleveland, Ohio Steven W. Schaefer, Diamond Shamrock, 1100 Superior Avenue, Cleveland, Ohio 44ll4 K. L. Spalding, Shell Chemical Co. One Shell Plaza, Houston, Texas 77001 Matt Swetonic, Hill & Knowlton, 633 Third Avenue, New York, N. Y. 10017 Todd C. Walker, Firestone Plastics Co. Box 699j Pottstown, Pa 19464 1. Acting Chairman Mr. Nuechterlein called on Messrs. Schafer and Heckman to review the draft bylaws for the permanent Polyvinyl Chloride Safety Group. Mr. Heckman's draft included many of the concepts in Mr. Schaefer's original with some minor changes to include principles used with other SPI committees, Mr. Nuechterlein suggested that a member of the Steering Committee be given overseeing responsibility for each of the standing subcommittees. He also suggested that all member companies be encouraged to actively participate in at least one of the standing subcommittees - not necessarily a bylaw item. Subcommittees to be included in bylaws: Steering . Manufacturing Practices Finance . Health Fire Safety . Nominating Public Relations The bylaws should include the concept of rotating Steering Committee members so as to provide continuity from year to year. 2. Health Committee Mr. Nuechterlein referred to his letter of January 11 establishing a Health Subcommittee with Dr. Ted Torkelson of Dow acting as Chairman. Other members include: Dr. Maurice Johnson Dr. Hinderer Mr. Mayo Smith Mr. R. N. Wheeler B. F. Goodrich Ethyl Corp Air Products & Chemicals Union Carbide Mr. Nuechterlein suggested that the Health Committee be requested to recommend what actions might be taken to clarify human health risks from vinyl chloride. -2SPI-10867 A compendium of Vinyl Chloride Toxicology Studies prepared by Dr. 'Corkclson was distributed for reference. (Copy attached). 3. Mr. Lawrence reviewed the plans for a visit of an EPA team to Dr. Maltoni on February lh, Request for U.S, industry representatives to be present has been made through John Stafford of ICI. (Note: This request was turned down bv CEFIC at.-its meetine held on February 3). redacted VJ1 redacted . Mr. Savage reported on the action being taken in the New Jersey legislature to pass a bill that would prohibit manufacturing concerns to use any of l6 named carcinogens including vinyl chloride. Companies with direct involvement (B. F. Goodrich, Hooker, PPG, Shell and Tenneco), have met in Trenton ar.d are working the New Jersey Chemical Industry Council to try to dis-involve vinyl chloride. Because the passage of such a bill in New Jersey would have a direct effect on the industry's ability to manufacture or process FVC in New Jersey and like wise because it might lead to similar action in other states, Mr. Savage suggested that up to $10,000 be allocated to support action on this concern. This request received a favorable vote by the Steering Committee. Mr. Savage distributed a copy of the report on New Jersey activities prepared by Don White (copy attached). 6. Mr. Ferrante reported on the activities of the Communications Committee in dicating that the media briefing have been halted temporarily because of the lack of specific positive information on the latest health issues. After discussion, it was agreed that the media briefings would continue even if it involves going without the doctor member of the briefing team. However, an attempt will be made to have the Health Committee develop interim responses to anticipated questions at its meeting to be held on February 17. Copies of the latest FVC Management Summary being mailed to all member companio were also distributed. 7. Mr. Heckman reviewed the status of the FDA Regulation on FVC as is being covered in his regular reports. It is his opinion that FDA may soon be moving to finalize its position on this regulation, 8. Mr. Nuechterlein indicated that he would appoint a nominating committee to prepare a slate of nominations for a new Steering Committee and the positions calledT'for in the proposed bylaws. % -4- SPI-10869 9 . It was agreed that a final version of the proposed bylaws be circulated to the full membership of the Producers Group by March 22 and that the full Group should meet in Washington, about mid-April. 10. The meeting adjourned at 3:30 P.M. Attachments 2/28/77 Respectfully submitted. CL JS ,, (/ John R. Lawrence Technical Director -5SPI-10870 toxicological studies in progress or unpublished j and Institution of iciple Investigator Source of Support Routs of Administration Species Dose Levels Duration of Treatment Nature of Study Starting Date Apparent Last Report Anticipated Tentative Conclusions Final ReoortTo Date L. Keplinger Justrial Bio Test rthbrook, Illinois U.s. Chemical Co. rough MCA Inhalation Rata 2500 files 200 C Hamsters 50 ppm 6 hr/day for 9-12 months; held for life time Carcinogenisis Lymphocyte transfor mation 9/1973 5/1976 (Oral) Overdue Excess tumors in both sexes of all three species; mice more susceptible than rats; rats more than hamstters. Histopathology incomplete. No evidence of lymphocyte transforaatic in rats at any dose. Bingham Iversity of Cincinnat k A/R. Tardlff -03-2143 Inhalation Rats 6000, 600 ppm Carcino gen isis; Teratogenisis; Trans* placental; Effect of Alcohol 5/1976 6/1976 Considerable pneumonia not related to exposure gewood Arsenal, MD SC/R.M. Hehir i dwest Research EHS/J.5. HOOdS I-ES-2-2084 Inhalation Rats, Mice 50,000 1 d to 5000, 50CI 20w 50 ppm Inhalation Rata, Mice 1000, 250,50 ppm selton OSH . Acute and short term exposure for carcinogenisis 3/1976 Carginogenisis, serial sacrifice for hestopathology 8/1976 Lata 1978 Mies severely affected after 6-8 SK>nths *0 oo and Institution of :iple Investigator >urce of Support Route of Administration TOXICOLOGICAL STUDIES IN PROGRESS OR UNPUBLISHED Species Dose Levels Duration of Treatment Nature of Study Starting Date Apparent Last Report Anticipated Final Report Cfl Tentative Conclusions To Date ire Haltonl* /ersity of Bologna r European Chemical sanies Inhalation BT 9 Inhalation *BT 15 Sprague Dawley Rats 50 ppm 4 hr/day for one year, kept for 48 add'1 weeks Carcinogenisis Sprague Dawley Rats 25,10, 5, 1 ppm 4 hr/day for one year, kept for 35 add'l weeks Carcinogenisis 9/1976 9/1976 Numerous tumors including mammary tumors Numerous tumors including mamnary tumors at 5 ppm and higher/ possibly tumors at 1 ppm Gavage BT 11 Sprague Dawley Rats 50-0.03 gAg/dy gavage in olive oil Daily for life-time Carcinogenisia Late 1973* Spring, 1975 Spring, 1976 Tumors at top Levels r. Maltoni has numer >1>ua other studies underway vinyl c iloride and ha i published he results of Experii ate were exposed for one year to 50 t< 10,000 Pi a and kep for the rest of their na tjural lifet. me. Nura: ngiosarcomas of the Livers, and nephr blastomas were obae rved as well a > an apparent excess of other turn era reported at any Level in Expertise t BT 1. tnt BT1. In Thi study Sprague Dawley ius tumors of this Zymbal glands, s. No increase in mammary tumors TOXICOLOGICAL STUDIES IN PROGRESS OR UNPUBLISHED e and institution of nciple Investigator Source of Suooort Route of Administration Species Dose Level8 Duration of Nature of Treatment Study Starting Date Apparent Last Report Anticipated Final Report Tentative Conclusions To Date IVO, Netherlands iuropean Companies hrough CEffXC Inhalation Ingestion Rats SOOO ppm Interim sacrifices for histopathology Rats 300 (gavage) 9,3 1 gAg/dy in PVC resin 84 seeks 90 weeks 8/1976 10/1976 Considerable mortality after 44 weeks. Harked liver pathology with neoplastic nodules * High mortality at 300 mgA day. Liver nodules at 3 mgA4/day and higher IRA, U.K. Ingestion Rats [n progress :io negri Institute ` Only proposal available EPIDEMIOLOGICAL STUDIES IM PROGRESS OR UNPUBLISHED Kae and/or Principle Investigator Source of Support Population Being Studied Factors Being Studied Final Report Consents Equitable Environmental Health (Formerly Tabershaw-Cooper) ------------ 10,183 male VCM production and polymeriration employees 31 U.S. Companies through MCA 672 death certificates 1942-1972; estimated exposure. cumulative exposure. latency 1st quarter 1977 Georgetown University; Male and Female PVC Organization Resources Counselors Fabricators --- Nine PlaBtic Manufacturer 3 4,592 death certificates 1964-1973; proportionate mortality Peb., 1976 95% followup; overall SMR 89; vinyl chloride appear to be a weak, general carcinogen; lung cancer and "other and unspecified" appear elevated. Anglosarcomas of liver occur in most heavily exposed grot The proportionate mortality analysis used in this at do not permit calculation of rates. Pre-selection factors limit analysis to rare diseases, such as angiosarcomas which were not found in this populate Laval University Residents in Shawinigan, Quebec Death certificates Ten angiosarcomas in PVC employees. Study on area residents in progress. (Laval University Birth Records In progress George Wirth --- ors 1 Residents in New England 7 t } Name and/or Principle Investigator Source of Support Population Being Studied MEDICAL STUDIES IN PROGRESS OR UNPUBLISHED Factors Being Studied Final Report Dr. Carlos Taadburro University of Louisville NCI end U.S. Industry (through MCA) BPS Production Employees Clinical Parameters Enzymes, Histology / t/a o 00 -I4h